MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD woul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology Jg. 78; H. 2; S. 84
Hauptverfasser:	Dickerson, Bradford C, Wolk, David A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 10.01.2012
Schlagworte:	Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - complications Alzheimer Disease - diagnosis Amyloid beta-Peptides - cerebrospinal fluid Biomarkers - cerebrospinal fluid Cerebral Cortex - pathology Cognition Disorders - cerebrospinal fluid Cognition Disorders - diagnosis Cognition Disorders - etiology Disease Progression Female Humans Magnetic Resonance Imaging Male Neuropsychological Tests Predictive Value of Tests Psychiatric Status Rating Scales Risk Factors
ISSN:	1526-632X, 1526-632X
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline. The Alzheimer's Disease Neuroimaging Initiative database was interrogated for CN individuals. MRI data were processed using a published set of a priori regions of interest to derive a single measure known as the AD signature (ADsig). Each individual was classified as ADsig-low (≥ 1 SD below the mean: high risk for preclinical AD), ADsig-average (within 1 SD of mean), or ADsig-high (≥ 1 SD above mean). A 3-year cognitive decline outcome was defined a priori using change in Clinical Dementia Rating sum of boxes and selected neuropsychological measures. Individuals at high risk for preclinical AD were more likely to experience cognitive decline, which developed in 21% compared with 7% of ADsig-average and 0% of ADsig-high groups (p = 0.03). Logistic regression demonstrated that every 1 SD of cortical thinning was associated with a nearly tripled risk of cognitive decline (p = 0.02). Of those for whom baseline CSF data were available, 60% of the high risk for preclinical AD group had CSF characteristics consistent with AD while 36% of the ADsig-average and 19% of the ADsig-high groups had such CSF characteristics (p = 0.1). This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD.
AbstractList	New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline.OBJECTIVENew preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline.The Alzheimer's Disease Neuroimaging Initiative database was interrogated for CN individuals. MRI data were processed using a published set of a priori regions of interest to derive a single measure known as the AD signature (ADsig). Each individual was classified as ADsig-low (≥ 1 SD below the mean: high risk for preclinical AD), ADsig-average (within 1 SD of mean), or ADsig-high (≥ 1 SD above mean). A 3-year cognitive decline outcome was defined a priori using change in Clinical Dementia Rating sum of boxes and selected neuropsychological measures.METHODSThe Alzheimer's Disease Neuroimaging Initiative database was interrogated for CN individuals. MRI data were processed using a published set of a priori regions of interest to derive a single measure known as the AD signature (ADsig). Each individual was classified as ADsig-low (≥ 1 SD below the mean: high risk for preclinical AD), ADsig-average (within 1 SD of mean), or ADsig-high (≥ 1 SD above mean). A 3-year cognitive decline outcome was defined a priori using change in Clinical Dementia Rating sum of boxes and selected neuropsychological measures.Individuals at high risk for preclinical AD were more likely to experience cognitive decline, which developed in 21% compared with 7% of ADsig-average and 0% of ADsig-high groups (p = 0.03). Logistic regression demonstrated that every 1 SD of cortical thinning was associated with a nearly tripled risk of cognitive decline (p = 0.02). Of those for whom baseline CSF data were available, 60% of the high risk for preclinical AD group had CSF characteristics consistent with AD while 36% of the ADsig-average and 19% of the ADsig-high groups had such CSF characteristics (p = 0.1).RESULTSIndividuals at high risk for preclinical AD were more likely to experience cognitive decline, which developed in 21% compared with 7% of ADsig-average and 0% of ADsig-high groups (p = 0.03). Logistic regression demonstrated that every 1 SD of cortical thinning was associated with a nearly tripled risk of cognitive decline (p = 0.02). Of those for whom baseline CSF data were available, 60% of the high risk for preclinical AD group had CSF characteristics consistent with AD while 36% of the ADsig-average and 19% of the ADsig-high groups had such CSF characteristics (p = 0.1).This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD.CONCLUSIONSThis approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD. New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline. The Alzheimer's Disease Neuroimaging Initiative database was interrogated for CN individuals. MRI data were processed using a published set of a priori regions of interest to derive a single measure known as the AD signature (ADsig). Each individual was classified as ADsig-low (≥ 1 SD below the mean: high risk for preclinical AD), ADsig-average (within 1 SD of mean), or ADsig-high (≥ 1 SD above mean). A 3-year cognitive decline outcome was defined a priori using change in Clinical Dementia Rating sum of boxes and selected neuropsychological measures. Individuals at high risk for preclinical AD were more likely to experience cognitive decline, which developed in 21% compared with 7% of ADsig-average and 0% of ADsig-high groups (p = 0.03). Logistic regression demonstrated that every 1 SD of cortical thinning was associated with a nearly tripled risk of cognitive decline (p = 0.02). Of those for whom baseline CSF data were available, 60% of the high risk for preclinical AD group had CSF characteristics consistent with AD while 36% of the ADsig-average and 19% of the ADsig-high groups had such CSF characteristics (p = 0.1). This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD.
Author	Dickerson, Bradford C Wolk, David A
Author_xml	– sequence: 1 givenname: Bradford C surname: Dickerson fullname: Dickerson, Bradford C email: USA.bradd@nmr.mgh.harvard.edu organization: Frontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer's Disease Research Center, and Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, USA.bradd@nmr.mgh.harvard.edu – sequence: 2 givenname: David A surname: Wolk fullname: Wolk, David A
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/22189451$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtLxDAYDKK4D_0HIrl56povafo4LqurC6uCD_QglDy-atw2XZtW8N9bcAVPMwwzAzMTsu8bj4ScAJsBB37-fLueMc1AoICMCyxNYvbIGCRPokTwl_1_fEQmIXwwNghpfkhGnEOWxxLG5PXmfkVN03bOqIp2785sPIZAtWtq1W6wpdsWrTNdoPOLqHIbpIuHJVXeDqk37zr3hdSiqZxH6jz1TVsPRcr2VReOyEGpqoDHO5ySp-Xl4-I6Wt9drRbzdWSkkF2U5aBjwyAGzWLUuS1BQGx0ZhMlmLCoQcgkzfIsVqhKIzTEmKYa0KASKuFTcvbbu22bzx5DV9QuGKwq5bHpQ5FzkKmUkg_O052z1zXaYtu6YeZ38XcI_wHGJGa0
CitedBy_id	crossref_primary_10_1093_cercor_bhae475 crossref_primary_10_1016_j_nicl_2016_05_017 crossref_primary_10_1016_j_biopsych_2019_08_015 crossref_primary_10_1016_j_dadm_2016_12_007 crossref_primary_10_1212_WNL_0000000000007010 crossref_primary_10_1016_j_tics_2013_08_007 crossref_primary_10_1503_jpn_150093 crossref_primary_10_3389_fnagi_2021_702796 crossref_primary_10_1007_s00401_024_02833_8 crossref_primary_10_1186_s13195_018_0444_1 crossref_primary_10_1212_WNL_0b013e31827b9147 crossref_primary_10_1371_journal_pcbi_1005350 crossref_primary_10_1016_j_nlm_2022_107620 crossref_primary_10_3233_JIFS_233000 crossref_primary_10_1007_s11682_014_9321_0 crossref_primary_10_1093_brain_awaa058 crossref_primary_10_1136_jnnp_2012_304418 crossref_primary_10_1038_s41537_020_00121_4 crossref_primary_10_1016_j_biopsych_2021_09_008 crossref_primary_10_1016_j_neurobiolaging_2014_08_031 crossref_primary_10_1017_S095925981400001X crossref_primary_10_1177_13872877251330500 crossref_primary_10_1212_WNL_0000000000006310 crossref_primary_10_1016_j_heliyon_2024_e26405 crossref_primary_10_1016_j_neuroimage_2014_02_028 crossref_primary_10_1016_j_nicl_2017_10_034 crossref_primary_10_1503_jpn_200165 crossref_primary_10_1016_j_jalz_2014_02_001 crossref_primary_10_1186_1750_1326_8_4 crossref_primary_10_1016_j_neurobiolaging_2023_05_004 crossref_primary_10_1016_j_bbi_2023_02_009 crossref_primary_10_1016_S1474_4422_14_70090_0 crossref_primary_10_3390_biology13100764 crossref_primary_10_3390_jcm9051424 crossref_primary_10_1001_jamanetworkopen_2019_17257 crossref_primary_10_3389_fnagi_2024_1441359 crossref_primary_10_1016_j_bbr_2014_12_006 crossref_primary_10_1155_2013_589308 crossref_primary_10_1016_j_nbd_2013_02_005 crossref_primary_10_1016_j_neurad_2025_101365 crossref_primary_10_1016_j_neurobiolaging_2016_06_011 crossref_primary_10_1134_S0006297922080089 crossref_primary_10_1002_hbm_23397 crossref_primary_10_1186_s13195_022_00972_2 crossref_primary_10_3233_JAD_210218 crossref_primary_10_1097_ACO_0b013e328362d183 crossref_primary_10_1016_j_nicl_2013_10_018 crossref_primary_10_3389_fneur_2025_1552940 crossref_primary_10_1007_s11682_017_9818_4 crossref_primary_10_1016_j_jalz_2014_11_001 crossref_primary_10_1186_s12889_024_19918_4 crossref_primary_10_1016_j_neurobiolaging_2018_09_021 crossref_primary_10_1176_appi_focus_19305 crossref_primary_10_1038_s41598_019_47294_2 crossref_primary_10_1016_j_neurobiolaging_2017_07_010 crossref_primary_10_1016_j_cogsys_2022_12_005 crossref_primary_10_1016_j_ncl_2013_07_001 crossref_primary_10_3389_fnagi_2023_1288295 crossref_primary_10_1016_j_jalz_2012_12_005 crossref_primary_10_1016_j_jad_2021_12_080 crossref_primary_10_1016_j_dadm_2018_08_013 crossref_primary_10_1016_j_biopsych_2014_08_024 crossref_primary_10_1002_dad2_12091 crossref_primary_10_3892_mmr_2018_9044 crossref_primary_10_1016_j_jagp_2023_07_008 crossref_primary_10_1111_nyas_14971 crossref_primary_10_1002_brb3_3506 crossref_primary_10_1016_j_jalz_2015_02_003 crossref_primary_10_1016_j_arr_2016_01_002 crossref_primary_10_1016_j_arr_2022_101651 crossref_primary_10_1016_j_envint_2020_105546 crossref_primary_10_1212_01_CON_0000429173_35439_9c crossref_primary_10_3390_ijms20225536 crossref_primary_10_1016_j_arr_2019_100964 crossref_primary_10_1016_j_neurobiolaging_2024_05_008 crossref_primary_10_1523_JNEUROSCI_4409_12_2013 crossref_primary_10_3389_fnhum_2022_907425 crossref_primary_10_1038_s41386_022_01452_9 crossref_primary_10_3233_JAD_190380 crossref_primary_10_1016_j_neurobiolaging_2018_08_005 crossref_primary_10_1002_hbm_22481 crossref_primary_10_1016_j_neurobiolaging_2018_01_017 crossref_primary_10_1016_j_ajp_2022_103396 crossref_primary_10_1002_hbm_26687 crossref_primary_10_1016_j_neuroimage_2013_02_059 crossref_primary_10_1371_journal_pone_0282363 crossref_primary_10_1016_j_jneuroling_2023_101190 crossref_primary_10_1016_j_neuroimage_2013_09_048 crossref_primary_10_4103_0972_6748_328840 crossref_primary_10_1007_s40815_017_0417_8 crossref_primary_10_1002_alz_13466 crossref_primary_10_1007_s00415_023_12087_1 crossref_primary_10_1212_WNL_0b013e3182a6cbfe crossref_primary_10_1002_alz_12777 crossref_primary_10_1016_j_acra_2013_12_001 crossref_primary_10_1016_j_neuron_2013_12_003 crossref_primary_10_1164_rccm_202406_1170OC crossref_primary_10_1016_j_neurobiolaging_2017_11_014 crossref_primary_10_1016_j_trci_2018_03_010 crossref_primary_10_1016_j_dadm_2016_03_001 crossref_primary_10_1016_j_bpsc_2025_06_010 crossref_primary_10_1177_25424823241290694 crossref_primary_10_3233_JAD_150238 crossref_primary_10_3390_ijms23147907 crossref_primary_10_3233_JAD_170545 crossref_primary_10_1016_j_jalz_2016_08_011 crossref_primary_10_1111_fcp_12654 crossref_primary_10_1016_j_nicl_2019_101895 crossref_primary_10_1016_j_neuroimage_2017_07_053 crossref_primary_10_1016_j_jns_2013_07_014 crossref_primary_10_1016_j_neuropsychologia_2013_11_016 crossref_primary_10_1007_s00429_013_0622_7 crossref_primary_10_1007_s10072_016_2477_1 crossref_primary_10_1016_j_nicl_2016_06_010 crossref_primary_10_1162_imag_a_00293 crossref_primary_10_3389_fnagi_2017_00146 crossref_primary_10_1016_j_neurobiolaging_2013_05_030 crossref_primary_10_3390_brainsci9090213 crossref_primary_10_1212_WNL_0b013e31824237a5 crossref_primary_10_1016_j_gerinurse_2025_03_013 crossref_primary_10_1371_journal_pone_0114721 crossref_primary_10_3233_JAD_160907 crossref_primary_10_1016_j_neuroimage_2022_119621 crossref_primary_10_1002_alz_12108 crossref_primary_10_1007_s00429_020_02148_w crossref_primary_10_1016_j_neuroscience_2015_11_067 crossref_primary_10_3233_JAD_200175 crossref_primary_10_3233_JAD_150824 crossref_primary_10_3390_brainsci14060590 crossref_primary_10_3233_JAD_180676 crossref_primary_10_1016_j_neurobiolaging_2013_06_015 crossref_primary_10_1016_j_neuropharm_2020_108081 crossref_primary_10_1371_journal_pone_0055398 crossref_primary_10_3233_JAD_210143 crossref_primary_10_1016_j_nicl_2013_11_010 crossref_primary_10_1016_S1474_4422_12_70291_0 crossref_primary_10_1093_brain_awac096 crossref_primary_10_1016_j_neurobiolaging_2025_01_001 crossref_primary_10_1016_j_neurobiolaging_2017_06_002 crossref_primary_10_1111_bpa_12249 crossref_primary_10_1016_j_jalz_2013_05_1769 crossref_primary_10_1016_j_jagp_2013_03_006 crossref_primary_10_12677_IJPN_2023_122002 crossref_primary_10_1016_j_neurobiolaging_2014_04_030 crossref_primary_10_3389_fnagi_2016_00015 crossref_primary_10_1016_j_biopsych_2013_11_020 crossref_primary_10_1016_j_jagp_2020_01_012 crossref_primary_10_1186_s13195_018_0406_7 crossref_primary_10_1016_j_dadm_2018_02_007 crossref_primary_10_1016_j_jash_2014_04_002 crossref_primary_10_3390_diagnostics8020041 crossref_primary_10_1186_1741_7015_10_127 crossref_primary_10_1186_s13195_023_01210_z crossref_primary_10_1016_j_neurobiolaging_2018_10_024 crossref_primary_10_1016_j_bspc_2023_105767 crossref_primary_10_1016_j_neuropsychologia_2013_02_014 crossref_primary_10_1371_journal_pcbi_1006376 crossref_primary_10_1016_j_jad_2024_01_021 crossref_primary_10_1016_j_bpsc_2022_06_007 crossref_primary_10_1007_s11042_024_20254_3
ContentType	Journal Article
Contributor	Jack, Jr, Clifford R Romirowsky, Aliza Schuff, Norbert Roberts, Peggy Kielb, Stephanie Shaw, Les Johnson, Kris Doody, Rachelle S Frank, Richard Molchan, Susan Chen, Kewei Duara, Ranjan Onyike, Chiadi Arnold, Steven E Jagust, William Mintun, Mark A Petrella, Jeffrey R Green, Robert C Grossman, Hillel Felmlee, Joel Pawluczyk, Sonia de Leon, Mony J Jicha, Greg Weiner, Michael Montine, Tom Dolen, Sara Varon, Daniel Oakley, Mary Ann Thompson, Paul DeCarli, Charles Fox, Nick Griffith, Randall Hardy, Peter Glodzik, Lidia Kachaturian, Zaven Mitsis, Effie Smith, Charles D Rusinek, Henry Wolk, David Korecka, Magdalena Schneider, Stacy Walter, Sarah Quinn, Joseph Bell, Karen L Villanueva-Meyer, Javier Liu, Enchi Bandy, Dan Neu, Scott Sather, Tamie Aisen, Paul Morris, John Stern, Yaakov Lord, Joanne L Marson, Daniel Reiman, Eric M Trojanowki, J Q Morris, John C Lopez, Oscar L Shah, Raj C Kornak, John Foster, Norm Mathis, Chet Foroud, Tatiana M Heidebrink, Judith Lee, Virginia M Y Kaye, Jeffrey Saykin, Andrew J Chowdhury, Munir Harvey, Danielle Koeppe, Robert A Potki
Contributor_xml	– sequence: 1 givenname: Michael surname: Weiner fullname: Weiner, Michael – sequence: 2 givenname: Paul surname: Aisen fullname: Aisen, Paul – sequence: 3 givenname: Enchi surname: Liu fullname: Liu, Enchi – sequence: 4 givenname: Robert C surname: Green fullname: Green, Robert C – sequence: 5 givenname: Tom surname: Montine fullname: Montine, Tom – sequence: 6 givenname: Ronald surname: Petersen fullname: Petersen, Ronald – sequence: 7 givenname: Anthony surname: Gamst fullname: Gamst, Anthony – sequence: 8 givenname: Ronald G surname: Thomas fullname: Thomas, Ronald G – sequence: 9 givenname: Michael surname: Donohue fullname: Donohue, Michael – sequence: 10 givenname: Sarah surname: Walter fullname: Walter, Sarah – sequence: 11 givenname: Devon surname: Gessert fullname: Gessert, Devon – sequence: 12 givenname: Tamie surname: Sather fullname: Sather, Tamie – sequence: 13 givenname: Laurel surname: Beckett fullname: Beckett, Laurel – sequence: 14 givenname: Danielle surname: Harvey fullname: Harvey, Danielle – sequence: 15 givenname: John surname: Kornak fullname: Kornak, John – sequence: 16 givenname: Clifford R surname: Jack, Jr fullname: Jack, Jr, Clifford R – sequence: 17 givenname: Anders surname: Dale fullname: Dale, Anders – sequence: 18 givenname: Matthew surname: Bernstein fullname: Bernstein, Matthew – sequence: 19 givenname: Joel surname: Felmlee fullname: Felmlee, Joel – sequence: 20 givenname: Nick surname: Fox fullname: Fox, Nick – sequence: 21 givenname: Paul surname: Thompson fullname: Thompson, Paul – sequence: 22 givenname: Norbert surname: Schuff fullname: Schuff, Norbert – sequence: 23 givenname: Gene surname: Alexander fullname: Alexander, Gene – sequence: 24 givenname: Charles surname: DeCarli fullname: DeCarli, Charles – sequence: 25 givenname: William surname: Jagust fullname: Jagust, William – sequence: 26 givenname: Dan surname: Bandy fullname: Bandy, Dan – sequence: 27 givenname: Robert A surname: Koeppe fullname: Koeppe, Robert A – sequence: 28 givenname: Norm surname: Foster fullname: Foster, Norm – sequence: 29 givenname: Eric M surname: Reiman fullname: Reiman, Eric M – sequence: 30 givenname: Kewei surname: Chen fullname: Chen, Kewei – sequence: 31 givenname: Chet surname: Mathis fullname: Mathis, Chet – sequence: 32 givenname: John surname: Morris fullname: Morris, John – sequence: 33 givenname: Nigel J surname: Cairns fullname: Cairns, Nigel J – sequence: 34 givenname: Lisa surname: Taylor-Reinwald fullname: Taylor-Reinwald, Lisa – sequence: 35 givenname: J Q surname: Trojanowki fullname: Trojanowki, J Q – sequence: 36 givenname: Les surname: Shaw fullname: Shaw, Les – sequence: 37 givenname: Virginia M Y surname: Lee fullname: Lee, Virginia M Y – sequence: 38 givenname: Magdalena surname: Korecka fullname: Korecka, Magdalena – sequence: 39 givenname: Arthur W surname: Toga fullname: Toga, Arthur W – sequence: 40 givenname: Karen surname: Crawford fullname: Crawford, Karen – sequence: 41 givenname: Scott surname: Neu fullname: Neu, Scott – sequence: 42 givenname: Andrew J surname: Saykin fullname: Saykin, Andrew J – sequence: 43 givenname: Tatiana M surname: Foroud fullname: Foroud, Tatiana M – sequence: 44 givenname: Steven surname: Potkin fullname: Potkin, Steven – sequence: 45 givenname: Li surname: Shen fullname: Shen, Li – sequence: 46 givenname: Zaven surname: Kachaturian fullname: Kachaturian, Zaven – sequence: 47 givenname: Richard surname: Frank fullname: Frank, Richard – sequence: 48 givenname: Peter J surname: Snyder fullname: Snyder, Peter J – sequence: 49 givenname: Susan surname: Molchan fullname: Molchan, Susan – sequence: 50 givenname: Jeffrey surname: Kaye fullname: Kaye, Jeffrey – sequence: 51 givenname: Sara surname: Dolen fullname: Dolen, Sara – sequence: 52 givenname: Joseph surname: Quinn fullname: Quinn, Joseph – sequence: 53 givenname: Lon S surname: Schneider fullname: Schneider, Lon S – sequence: 54 givenname: Sonia surname: Pawluczyk fullname: Pawluczyk, Sonia – sequence: 55 givenname: Bryan M surname: Spann fullname: Spann, Bryan M – sequence: 56 givenname: James surname: Brewer fullname: Brewer, James – sequence: 57 givenname: Helen surname: Vanderswag fullname: Vanderswag, Helen – sequence: 58 givenname: Judith surname: Heidebrink fullname: Heidebrink, Judith – sequence: 59 givenname: Joanne L surname: Lord fullname: Lord, Joanne L – sequence: 60 givenname: Kris surname: Johnson fullname: Johnson, Kris – sequence: 61 givenname: Rachelle S surname: Doody fullname: Doody, Rachelle S – sequence: 62 givenname: Javier surname: Villanueva-Meyer fullname: Villanueva-Meyer, Javier – sequence: 63 givenname: Munir surname: Chowdhury fullname: Chowdhury, Munir – sequence: 64 givenname: Yaakov surname: Stern fullname: Stern, Yaakov – sequence: 65 givenname: Lawrence S surname: Honig fullname: Honig, Lawrence S – sequence: 66 givenname: Karen L surname: Bell fullname: Bell, Karen L – sequence: 67 givenname: John C surname: Morris fullname: Morris, John C – sequence: 68 givenname: Mark A surname: Mintun fullname: Mintun, Mark A – sequence: 69 givenname: Stacy surname: Schneider fullname: Schneider, Stacy – sequence: 70 givenname: Daniel surname: Marson fullname: Marson, Daniel – sequence: 71 givenname: Randall surname: Griffith fullname: Griffith, Randall – sequence: 72 givenname: David surname: Clark fullname: Clark, David – sequence: 73 givenname: Hillel surname: Grossman fullname: Grossman, Hillel – sequence: 74 givenname: Effie surname: Mitsis fullname: Mitsis, Effie – sequence: 75 givenname: Aliza surname: Romirowsky fullname: Romirowsky, Aliza – sequence: 76 givenname: Leyla surname: deToledo-Morrell fullname: deToledo-Morrell, Leyla – sequence: 77 givenname: Raj C surname: Shah fullname: Shah, Raj C – sequence: 78 givenname: Ranjan surname: Duara fullname: Duara, Ranjan – sequence: 79 givenname: Daniel surname: Varon fullname: Varon, Daniel – sequence: 80 givenname: Peggy surname: Roberts fullname: Roberts, Peggy – sequence: 81 givenname: Marilyn surname: Albert fullname: Albert, Marilyn – sequence: 82 givenname: Chiadi surname: Onyike fullname: Onyike, Chiadi – sequence: 83 givenname: Stephanie surname: Kielb fullname: Kielb, Stephanie – sequence: 84 givenname: Henry surname: Rusinek fullname: Rusinek, Henry – sequence: 85 givenname: Mony J surname: de Leon fullname: de Leon, Mony J – sequence: 86 givenname: Lidia surname: Glodzik fullname: Glodzik, Lidia – sequence: 87 givenname: P surname: Murali Doraiswamy fullname: Murali Doraiswamy, P – sequence: 88 givenname: Jeffrey R surname: Petrella fullname: Petrella, Jeffrey R – sequence: 89 givenname: Steven E surname: Arnold fullname: Arnold, Steven E – sequence: 90 givenname: Jason H surname: Karlawish fullname: Karlawish, Jason H – sequence: 91 givenname: David surname: Wolk fullname: Wolk, David – sequence: 92 givenname: Charles D surname: Smith fullname: Smith, Charles D – sequence: 93 givenname: Greg surname: Jicha fullname: Jicha, Greg – sequence: 94 givenname: Peter surname: Hardy fullname: Hardy, Peter – sequence: 95 givenname: Oscar L surname: Lopez fullname: Lopez, Oscar L – sequence: 96 givenname: Mary Ann surname: Oakley fullname: Oakley, Mary Ann
CorporateAuthor	Alzheimer's Disease Neuroimaging Initiative
CorporateAuthor_xml	– name: Alzheimer's Disease Neuroimaging Initiative
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1212/WNL.0b013e31823efc6c
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1526-632X
ExternalDocumentID	22189451
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIA NIH HHS grantid: R01 AG022374 – fundername: NIA NIH HHS grantid: K23-AG028018 – fundername: NIA NIH HHS grantid: R21-AG29840 – fundername: NCATS NIH HHS grantid: UL1 TR001998 – fundername: NIA NIH HHS grantid: P30 AG019610 – fundername: NIA NIH HHS grantid: U01 AG024904 – fundername: NIA NIH HHS grantid: K01 AG030514 – fundername: NCATS NIH HHS grantid: UL1 TR000117 – fundername: NIA NIH HHS grantid: P30AG010124 – fundername: NIA NIH HHS grantid: P50-AG005134
GroupedDBID	--- -~X .XZ .Z2 01R 0R~ 123 1J1 29N 354 3PY 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 77Y AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAWTL AAXQO AAYEP ABBLC ABIVO ABJNI ABOCM ABVCZ ACCJW ACDDN ACGFS ACIJW ACILI ACLDA ACOAL ACWRI ACXJB ADGGA ADNKB AE6 AEBDS AENEX AFDTB AFEXH AFFNX AFUWQ AGINI AHOMT AHQNM AHVBC AIJEX AJCLO AKCTQ AKULP AKWKN ALMA_UNASSIGNED_HOLDINGS AMJPA AMKUR AMNEI AOHHW AWKKM BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIWNM DU5 E.X EBS ECM EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FW0 GQDEL HZ~ IKYAY IN~ JF7 KD2 KMI L-C L7B N9A NEJ NPM N~7 N~B O9- OAG OAH OBH ODMTH OHH OHYEH OJAPA OL1 OLB OLH OLU OLV OLW OLY OLZ OPX OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P2P RHI RLZ RXW SJN TEORI V2I VVN VXZ W3M WH7 WOQ WOW XOL XSW XXN XYM XYN YBU YCJ YFH ~9M 7X8 ABPXF ABXYN ABZZY ACZKN ADKSD ADSXY AFNMH AHQVU
ID	FETCH-LOGICAL-c535t-891b4c0141b04eb9df1314cb8d6a303deb135678984aeafc3b14e77b1ecea3a62
IEDL.DBID	7X8
ISICitedReferencesCount	173
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000299159700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1526-632X
IngestDate	Thu Oct 02 10:00:34 EDT 2025 Wed Feb 19 02:41:50 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c535t-891b4c0141b04eb9df1314cb8d6a303deb135678984aeafc3b14e77b1ecea3a62
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://n.neurology.org/content/neurology/78/2/84.full.pdf
PMID	22189451
PQID	921575552
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_921575552 pubmed_primary_22189451
PublicationCentury	2000
PublicationDate	2012-01-10
PublicationDateYYYYMMDD	2012-01-10
PublicationDate_xml	– month: 01 year: 2012 text: 2012-01-10 day: 10
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Neurology
PublicationTitleAlternate	Neurology
PublicationYear	2012
References	19260027 - Ann Neurol. 2009 Feb;65(2):176-83 11476837 - Lancet. 2001 Jul 21;358(9277):201-5 22189450 - Neurology. 2012 Jan 10;78(2):80-1 11459114 - J Int Neuropsychol Soc. 2001 Jul;7(5):631-9 20479234 - Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10256-61 16247049 - Neurology. 2005 Oct 25;65(8):1227-31 19376612 - Neurobiol Aging. 2009 Jul;30(7):1026-36 18302232 - J Magn Reson Imaging. 2008 Apr;27(4):685-91 8618671 - Neurology. 1996 Mar;46(3):707-19 21181717 - Ann Neurol. 2010 Dec;68(6):825-34 20934914 - Lancet Neurol. 2010 Nov;9(11):1118-27 18809227 - Neurobiol Aging. 2010 Jul;31(7):1099-106 3185902 - Neurology. 1988 Nov;38(11):1682-7 18814937 - Neurobiol Aging. 2010 Jul;31(7):1077-88 8232972 - Neurology. 1993 Nov;43(11):2412-4 21514248 - Alzheimers Dement. 2011 May;7(3):280-92 17438217 - Neurology. 2007 Apr 17;68(16):1268-73 15236399 - Ann Neurol. 2004 Jul;56(1):27-35 9010004 - Brain. 1996 Dec;119 ( Pt 6):2001-7 17846109 - J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):630-5 12557284 - Ann Neurol. 2003 Feb;53(2):181-8 1961359 - Neurobiol Aging. 1991 Jul-Aug;12(4):295-312 17562935 - Arch Neurol. 2007 Jun;64(6):862-71 18632739 - Cereb Cortex. 2009 Mar;19(3):497-510 19109536 - Neurology. 2009 Mar 24;72(12):1048-55 19296504 - Ann Neurol. 2009 Apr;65(4):403-13 20008650 - Arch Neurol. 2009 Dec;66(12):1469-75 16801647 - Neurology. 2006 Jun 27;66(12):1837-44 21490323 - Neurology. 2011 Apr 19;76(16):1395-402 9153461 - Neurology. 1997 May;48(5):1297-304 20562467 - J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):45-51 11559310 - Arch Neurol. 2001 Sep;58(9):1395-402 18056553 - Arch Gen Psychiatry. 2007 Dec;64(12):1443-50 16389197 - Arch Gen Psychiatry. 2006 Jan;63(1):57-62
References_xml	– reference: 11459114 - J Int Neuropsychol Soc. 2001 Jul;7(5):631-9 – reference: 21514248 - Alzheimers Dement. 2011 May;7(3):280-92 – reference: 8232972 - Neurology. 1993 Nov;43(11):2412-4 – reference: 9153461 - Neurology. 1997 May;48(5):1297-304 – reference: 18809227 - Neurobiol Aging. 2010 Jul;31(7):1099-106 – reference: 17562935 - Arch Neurol. 2007 Jun;64(6):862-71 – reference: 18814937 - Neurobiol Aging. 2010 Jul;31(7):1077-88 – reference: 21181717 - Ann Neurol. 2010 Dec;68(6):825-34 – reference: 19376612 - Neurobiol Aging. 2009 Jul;30(7):1026-36 – reference: 3185902 - Neurology. 1988 Nov;38(11):1682-7 – reference: 15236399 - Ann Neurol. 2004 Jul;56(1):27-35 – reference: 20008650 - Arch Neurol. 2009 Dec;66(12):1469-75 – reference: 17846109 - J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):630-5 – reference: 19109536 - Neurology. 2009 Mar 24;72(12):1048-55 – reference: 18302232 - J Magn Reson Imaging. 2008 Apr;27(4):685-91 – reference: 11476837 - Lancet. 2001 Jul 21;358(9277):201-5 – reference: 22189450 - Neurology. 2012 Jan 10;78(2):80-1 – reference: 11559310 - Arch Neurol. 2001 Sep;58(9):1395-402 – reference: 16389197 - Arch Gen Psychiatry. 2006 Jan;63(1):57-62 – reference: 16801647 - Neurology. 2006 Jun 27;66(12):1837-44 – reference: 9010004 - Brain. 1996 Dec;119 ( Pt 6):2001-7 – reference: 1961359 - Neurobiol Aging. 1991 Jul-Aug;12(4):295-312 – reference: 18632739 - Cereb Cortex. 2009 Mar;19(3):497-510 – reference: 17438217 - Neurology. 2007 Apr 17;68(16):1268-73 – reference: 19296504 - Ann Neurol. 2009 Apr;65(4):403-13 – reference: 16247049 - Neurology. 2005 Oct 25;65(8):1227-31 – reference: 20479234 - Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10256-61 – reference: 20934914 - Lancet Neurol. 2010 Nov;9(11):1118-27 – reference: 20562467 - J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):45-51 – reference: 8618671 - Neurology. 1996 Mar;46(3):707-19 – reference: 19260027 - Ann Neurol. 2009 Feb;65(2):176-83 – reference: 21490323 - Neurology. 2011 Apr 19;76(16):1395-402 – reference: 18056553 - Arch Gen Psychiatry. 2007 Dec;64(12):1443-50 – reference: 12557284 - Ann Neurol. 2003 Feb;53(2):181-8
SSID	ssj0015279
Score	2.4753838
Snippet	New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	84
SubjectTerms	Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - complications Alzheimer Disease - diagnosis Amyloid beta-Peptides - cerebrospinal fluid Biomarkers - cerebrospinal fluid Cerebral Cortex - pathology Cognition Disorders - cerebrospinal fluid Cognition Disorders - diagnosis Cognition Disorders - etiology Disease Progression Female Humans Magnetic Resonance Imaging Male Neuropsychological Tests Predictive Value of Tests Psychiatric Status Rating Scales Risk Factors
Title	MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults
URI	https://www.ncbi.nlm.nih.gov/pubmed/22189451 https://www.proquest.com/docview/921575552
Volume	78
WOSCitedRecordID	wos000299159700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agv9uB1sclms8lJSrUo2FB8YA5C2N3MQmlJa1P9_c6maXsSD16SSxaWYXa-LzvfzBByHfgqssJaFnIbMtdDiilpgBlPIR4JCzLKq2ETMkmiNI37tTanrGWVi5hYBep8bNwd-U2M2CSFEP7t5JO5oVEuuVpP0FgnDe4SbujOMl0lEYRftdrDd4hb8dO6cg6D9c178rS6AvQ5WBOa3zlmhTXd3X_uco_s1CSTtudesU_WoDggW706jX5IPnrPjxR_O6t7bOoU70MX8airxXdynSmdTN3Hs5K279hoMATaeelSVeR0KTeiObiqSqCDghaO-I5o1cujPCJv3fvXzgOrxywwI7iYsSj2dGCc4FO3AtBxbj3uBUZHeagQ4HKM5lwgpsVRoEBZw7UXgJTaAwOKq9A_JhvFuIBTQkHbEKQNtevxE_NY5UZyXCZ0yyIvbTUJXZgtQzd2uQlVwPirzJaGa5KTuemzybzdRuYjC4kD4Z39vficbCOhcVoThJcL0rB4hOGSbJrv2aCcXlXugc-k3_sBFvTFUA
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MRI+cortical+thickness+biomarker+predicts+AD-like+CSF+and+cognitive+decline+in+normal+adults&rft.jtitle=Neurology&rft.au=Dickerson%2C+Bradford+C&rft.au=Wolk%2C+David+A&rft.date=2012-01-10&rft.eissn=1526-632X&rft.volume=78&rft.issue=2&rft.spage=84&rft_id=info:doi/10.1212%2FWNL.0b013e31823efc6c&rft_id=info%3Apmid%2F22189451&rft_id=info%3Apmid%2F22189451&rft.externalDocID=22189451
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1526-632X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1526-632X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1526-632X&client=summon